Back to Search Start Over

NCCN GuidelinesĀ® Insights: Hematopoietic Growth Factors, Version 1.2022.

Authors :
Griffiths EA
Roy V
Alwan L
Bachiashvili K
Baird J
Cool R
Dinner S
Geyer M
Glaspy J
Gojo I
Hicks A
Kallam A
Kidwai WZ
Kloth DD
Kraut EH
Landsburg D
Lyman GH
Mahajan A
Miller R
Nachar V
Patel S
Patel S
Perez LE
Poust A
Riaz F
Rosovsky R
Rugo HS
Simon S
Vasu S
Wadleigh M
Westbrook K
Westervelt P
Berardi RA
Pluchino L
Source :
Journal of the National Comprehensive Cancer Network : JNCCN [J Natl Compr Canc Netw] 2022 May; Vol. 20 (5), pp. 436-442.
Publication Year :
2022

Abstract

The NCCN Guidelines for Hematopoietic Growth Factors provide recommendations for the appropriate use of growth factors in the clinical management of febrile neutropenia (FN), chemotherapy-induced thrombocytopenia (CIT), and chemotherapy-induced anemia (CIA). Management and prevention of these sequelae are an integral part of supportive care for many patients undergoing cancer treatment. The purpose of these guidelines is to operationalize the evaluation, prevention, and treatment of FN, CIT, and CIA in adult patients with nonmyeloid malignancies and to enable the patient and clinician to assess management options for FN, CIT, and CIA in the context of an individual patient's condition. These NCCN Guidelines Insights provide a summary of the important recent updates to the NCCN Guidelines for Hematopoietic Growth Factors, with particular emphasis on the incorporation of a newly developed section on CIT.

Details

Language :
English
ISSN :
1540-1413
Volume :
20
Issue :
5
Database :
MEDLINE
Journal :
Journal of the National Comprehensive Cancer Network : JNCCN
Publication Type :
Academic Journal
Accession number :
35545171
Full Text :
https://doi.org/10.6004/jnccn.2022.0026